Introduction {#S1}
============

Pemphigus vulgaris (PV) is a potentially life-threatening blistering disease caused by autoantibodies against desmoglein (Dsg) adhesion proteins. Pathogenic anti-Dsg antibodies disrupt the assembly of Dsg into nascent desmosomes, resulting in desmosome disassembly and loss of intercellular adhesion ([@R14];[@R6];[@R7];[@R17]), evidenced histologically as suprabasal acantholysis. Pathogenic serum IgG antibodies bind calcium-sensitive conformational epitopes in the Dsg extracellular amino-terminal domains, while nonpathogenic serum IgG bind non-conformational epitopes throughout the extracellular domains ([@R1];[@R2]). Anti-Dsg monoclonal antibodies (mAbs) that bind amino-terminal calcium-sensitive epitopes and cause suprabasal acantholysis have been identified from an active immune mouse model of PV ([@R29]), as well as human PV patients ([@R20];[@R32]).

Skin adhesion is weakened even in the non-blistered skin of pemphigus patients, as blisters can be induced in normal-appearing skin by mechanical shear stress (known as the Nikolsky sign). However, blisters also spontaneously occur in pemphigus patients, even in the absence of mechanical shear stress. Past studies have implicated diverse signaling pathways in PV IgG-induced acantholysis, including p38 mitogen-activated protein kinase ([@R4]), rho family GTPases ([@R30]), protein kinase C ([@R24]), and c-myc ([@R31]), among others ([@R25]). Of these, a role for p38 has been the best established, with data from multiple laboratories supporting necessary and sufficient roles for p38 in various aspects of pemphigus pathology. p38 is activated in *in vitro* studies using PV serum IgG and mAbs ([@R4];[@R12];[@R18]) and *in vivo* in pemphigus patient skin ([@R3]). Exogenous p38 activation by oxidative stress or ultraviolet light causes Dsg3 endocytosis in keratinocytes ([@R18]), and p38 inhibition prevents pathologic effects of PV serum IgG and mAbs, including Dsg3 endocytosis and blistering in a mouse passive transfer model ([@R5];[@R11];[@R18]). Recent studies by our laboratory and others have proposed that steric hindrance of Dsg3 adhesion (pathophysiologically equivalent to the Nikolsky sign in patients) is signaling-independent ([@R18];[@R23];[@R10]), whereas spontaneous blistering is amplified by p38 signaling, which may explain the therapeutic benefit of p38 inhibition in some but not all PV models.

Currently, rapid control of pemphigus blistering is achieved with corticosteroids, although the immunosuppressive and hyperglycemic side effects of corticosteroids can cause complications, making p38 a promising adjunctive target for therapy in PV. However, p38 inhibitors have systemic toxicities in humans ([@R9]), due to p38's involvement in a broad range of cellular processes and p38 inhibitor promiscuity, leading to off-target effects. Additionally, p38 has four isoforms (α, β, γ, and δ), which complicate its study in biological systems. Therefore, we sought to identify downstream effectors that regulate Dsg3 endocytosis and keratinocyte adhesion, which could be more specific targets for therapeutic intervention. MAPKAP kinase 2 (MK2) regulates several cellular events downstream of p38 signaling, including tumor necrosis factor alpha production and cytoskeletal remodeling, both of which may contribute to PV pathogenesis ([@R16];[@R13]). In the present study, we identify MK2 as the major downstream effector of p38 signaling in PV and describe MK2-dependent and -independent mechanisms of blister formation.

Results {#S2}
=======

MK2 is activated in lesional keratinocytes of pemphigus patients {#S3}
----------------------------------------------------------------

To determine whether MK2 is activated *in vivo* in pemphigus, we performed immunohistochemistry on skin biopsies from 4 PV patients and 2 patients with the related blistering disease, pemphigus foliaceus (PF), to detect activated (phospho-Thr222) MK2. Normal rabbit serum was a primary antibody control ([Figure 1](#F1){ref-type="fig"}, left panels). Activated MK2 was observed in keratinocytes in the blister roof and base of PV and PF patients (arrows). MK2 phosphorylation was not observed in PV non-lesional epidermis, as compared to normal human epidermis, although slight elevation of activated MK2 was observed in perilesional keratinocytes (PV non-lesional, arrows).

Pathogenic anti-Dsg PV mAb activates MK2 in a dose-dependent manner in primary human epidermal keratinocytes (PHEK), causing translocation of MK2 from the nucleus to the cytoplasm {#S4}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Previously, we cloned human anti-Dsg single chain variable fragment (scFv) mAbs from PV patients ([@R20]). Similar to PV serum IgG, pathogenic scFv mAbs cause Dsg3 endocytosis, dissociation of PHEK, and suprabasal blisters in human skin explants and neonatal mice after passive transfer ([@R20];[@R17]). Pathogenic scFv, IgG1, and IgG4 mAbs expressing the same variable region activate p38 MAPK in PHEK with equivalent dose-dependency ([@R18]). In contrast, nonpathogenic mAbs bind Dsg3 but do not activate p38, cause Dsg endocytosis, or induce skin blisters. We first determined whether a pathogenic IgG4 mAb (recognizing both Dsg3 and Dsg1) that activates p38 and causes skin blisters also activates MK2, by immunoblotting PHEK lysates with an antibody specific for activated MK2, using total MK2 protein as a loading control. Oxidative stress (200 μM H~2~O~2~) was a positive control and nonpathogenic anti-Dsg3/1 IgG4 mAb a negative control for stimulating p38/MK2 signaling. Both the pathogenic mAb and H~2~O~2~ activated MK2 in a dose-dependent manner ([Figure 2A](#F2){ref-type="fig"}, upper panels), with peak activation at 2 hours ([Figure 2B](#F2){ref-type="fig"}). Activation of p38 showed a similar pattern ([Figure 2A](#F2){ref-type="fig"}, lower panels).

Activation of MK2 causes its translocation from the nucleus to the cytoplasm ([@R8]). We therefore performed subcellular fractionation of PHEK after pathogenic mAb stimulation. Before PV mAb treatment, MK2 is predominantly located in the nucleus ([Figure 2B](#F2){ref-type="fig"}, 0 hrs). 4--16 hours after pathogenic PV mAb stimulation, MK2 protein shifts from the nuclear to cytosolic fractions. Similarly, MK2, detected by immunofluorescence staining, remains in the nucleus in PHEK treated with nonpathogenic mAb ([Figure 2C](#F2){ref-type="fig"}). Upon activation by pathogenic mAb or H~2~O~2~, MK2 translocates to the cytoplasm. Similar findings are observed *in vivo*, as activated MK2 is predominantly localized in the cytoplasm of lesional keratinocytes in pemphigus patient skin ([Figure 1](#F1){ref-type="fig"}, PV4 and PF1 insets).

Inhibition or knockdown of MK2 prevents PV mAb-mediated loss of cell surface Dsg3 in human keratinocytes {#S5}
--------------------------------------------------------------------------------------------------------

If MK2 is the primary downstream effector of p38 signaling in PV, then MK2 inhibition should prevent the pathologic effects of PV mAbs that are regulated by p38, including Dsg3 endocytosis and loss of Dsg3 from the desmosomal fraction of PHEK ([@R11];[@R18]). We first examined the efficacy and specificity of a pyrrolopyridinyl MK2 inhibitor. The MK2 inhibitor (MK2I) decreases phosphorylation of HSP27, a direct downstream target of MK2, in a dose-dependent pattern ([Figure 3A](#F3){ref-type="fig"}; total HSP27 as a loading control), but does not affect the phosphorylation of the upstream kinase p38. Treatment of PHEK with the p38 inhibitor SB202190 or MK2I decreases the loss of Dsg3 and desmoplakin from the Triton-insoluble fraction of PHEK ([Figure 3B](#F3){ref-type="fig"}, upper panels). Consistent with these findings, MK2 inhibition prevents the pathogenic PV mAb-mediated loss of cell-surface Dsg3, similar to the effects of p38 inhibition ([Figure 3C](#F3){ref-type="fig"}).

To confirm the inhibitor studies, we used shRNA to silence MK2 expression in HaCat human keratinocytes. MK2 protein levels were determined by immunoblotting, using histone H3 as a control. Compared to the control (Ctl) shRNA-transfected cell line, MK2 expression was almost completely silenced in the MK2 shRNA stable cell line ([Figure 4A](#F4){ref-type="fig"}, upper panel). p38 expression is also significantly decreased in MK2 shRNA cells, which was unanticipated but consistent with prior reports indicating that MK2 stabilizes p38 protein ([@R15]). MK2 knockdown was further confirmed by immunofluorescence staining ([Figure 4B](#F4){ref-type="fig"}). MK2 shRNA and control cells were treated with PBS, H~2~0~2~, or PV pathogenic mAb, and the subcellular location of Dsg3 was determined by immunostaining. Both H~2~0~2~ and PV mAb-induced loss of cell surface Dsg3 were decreased in MK2 shRNA cells compared to control cells ([Figure 4C](#F4){ref-type="fig"}), consistent with the results of p38 and MK2 small molecule inhibition.

Genetic deletion or small molecule inhibition of MK2 does not inhibit induced blisters in a mouse passive transfer model {#S6}
------------------------------------------------------------------------------------------------------------------------

Mice can develop both Nikolsky and spontaneous suprabasal blisters after passive transfer of PV mAbs. 4--6 hours after passive transfer, Nikolsky skin fragility occurs (induction of blisters by mechanical shear stress). 16--18 hours after passive transfer, spontaneous blisters appear (in the absence of applied mechanical shear stress). Previously, we demonstrated that Nikolsky skin fragility is p38α-independent ([@R18]). Similarly, mice with a genetic deletion of MK2 ([@R16]) are susceptible to induced suprabasal blisters after passive transfer of pathogenic PV mAb ([Figure 5A](#F5){ref-type="fig"}). 6/6 wild-type and 4/4 MK2-knockout mice demonstrated gross blisters, with suprabasal acantholysis and similar histology scores ([Figure 5B--C](#F5){ref-type="fig"}).

Because MK2-deficient mice demonstrate decreased p38 levels, we also tested whether inhibition of MK2 signaling, which does not affect p38 activation ([Figure 3A](#F3){ref-type="fig"}), can block induced blisters. We injected wild-type mice with PV mAbs, two hours after injection with 5μg of p38 inhibitor (SB202190) or 6.25μg of MK2I (doses determined by *in vitro* assays confirming sufficiency of kinase inhibition ([Figure 3A](#F3){ref-type="fig"}) relative to effective *in vivo* doses of p38 inhibitors ([@R5])). Similar to MK2-knockout mice, wild-type mice pretreated with DMSO or MK2I then pathogenic (P) mAb develop blisters after mechanical shear stress ([Figure 5D](#F5){ref-type="fig"}). 5/5 DMSO+P and 5/5 MK2I+P mice demonstrated gross blisters, again with suprabasal acantholysis and similar histology scores ([Figure 5E--F](#F5){ref-type="fig"}). Direct immunofluorescence analysis confirmed mAb binding (data not shown).

Genetic deletion or inhibition of MK2 inhibits spontaneous blister formation in a mouse passive transfer model {#S7}
--------------------------------------------------------------------------------------------------------------

We next determined whether MK2 is required for spontaneous blistering in the mouse passive transfer model. In contrast to induced blisters, spontaneous blistering was significantly reduced in MK2 knockout mice compared to wild-type littermate controls ([Figure 6A](#F6){ref-type="fig"}). 25/30 wild-type mice showed gross blisters after passive transfer of pathogenic mAb, compared to 4/15 MK2-knockout mice (p=0.0005). Direct immunofluorescence analysis of skin confirmed mAb binding (data not shown). All 30 wild-type mice demonstrated suprabasal acantholysis, with significantly increased histologic blistering ([Figure 6B--C](#F6){ref-type="fig"}). MK2-knockout mice without gross blisters did not demonstrate microscopic blisters. Unexpectedly, MK2-knockout mice with gross blisters demonstrated predominantly superficial, with focal areas of suprabasal, acantholysis ([Figure 6B](#F6){ref-type="fig"}, bottom right). This phenotype was also observed in mice with a K14-Cre mediated deletion of p38α in the epidermis after injection with pathogenic mAb (see [Supplemental Text](#SD1){ref-type="supplementary-material"}, [Figure S1](#SD1){ref-type="supplementary-material"}, for full discussion.) The extent of suprabasal blistering in MK2-knockout mice was significantly reduced compared to wild-type mice ([Figure 6C](#F6){ref-type="fig"}).

We then tested whether spontaneous blisters are dependent on MK2 signaling. Wild-type mice injected with pathogenic but not nonpathogenic mAb developed spontaneous blisters 16--18 hours after passive transfer ([Figure 6D](#F6){ref-type="fig"}). Pre-treatment with SB202190 (a p38 inhibitor) or MK2I inhibited blister formation. 7/8 mice injected with pathogenic mAb demonstrated gross blistering, whereas 2/8 mice injected with MK2I and 1/4 with SB202190 then pathogenic mAb blistered (p\<0.05). Histologic analysis confirmed inhibition of blistering ([Figure 6E--F](#F6){ref-type="fig"}), although focal suprabasal acantholysis was observed on the edge of some tissue specimens, consistent with Nikolsky skin fragility due to tissue processing. Direct immunofluorescence confirmed binding of mAbs to the keratinocyte cell surface (data not shown).

We attempted to evaluate whether PV serum IgG is similarly blocked by MK2 deficiency or inhibition. However, two PV serum IgG samples that caused suprabasal blisters in human skin explants did not cause suprabasal blisters in mice, due to lack of cross-reactivity or low affinity binding to mouse compared to human Dsg3 (data not shown).

Discussion {#S8}
==========

In this study, we describe signaling-dependent and --independent models of blister formation in PV and identify MK2 as the major downstream effector of p38-dependent pathology in PV. Pathogenic PV autoantibodies activate MK2 *in vivo* in the skin of PV patients and mice after passive transfer ([Figure 1](#F1){ref-type="fig"} and [Figure S1](#SD1){ref-type="supplementary-material"}) and *in vitro* in PHEK ([Figure 2A](#F2){ref-type="fig"}). MK2 is activated by phosphorylation of residue Thr222 and Thr334 by p38. Phosphorylation of Thr334, which regulates the nuclear localization and nuclear export signals of MK2, results in translocation of MK2 from the nucleus to the cytoplasm ([@R15]). Accordingly, MK2 translocates from the nucleus to cytoplasm in response to pathogenic PV mAb ([Figure 2](#F2){ref-type="fig"}) and is predominantly localized in the cytoplasm of lesional keratinocytes in pemphigus patient skin ([Figure 1](#F1){ref-type="fig"}).

Additionally, we demonstrate that MK2 inhibition, using both small molecule and genetic approaches, prevents loss of cell surface Dsg3 ([Figures 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}) and spontaneous blister formation in a mouse passive transfer PV model ([Figure 6](#F6){ref-type="fig"}). The specificity of MK2 small molecule inhibition is supported by our studies using shRNA knockdown or genetic deletion of MK2, although MK2 cannot be uniquely targeted by genetic approaches since its knockdown results in simultaneous destabilization of p38 ([Figure 4A](#F4){ref-type="fig"}) ([@R15];[@R22]). Nevertheless, the MK2 silencing, knockout, and inhibitor studies all demonstrate a consistent protective phenotype in regard to maintenance of keratinocyte cell surface Dsg3 and spontaneous blistering, which collectively support a role for the p38-MK2 signaling pathway in PV pathogenesis. It is interesting that genetic loss of MK2 and p38α in mouse epidermis may be more protective for suprabasal than superficial blistering ([Figure 6](#F6){ref-type="fig"} and [S1](#SD1){ref-type="supplementary-material"}). This selective phenotype was not observed with MK2 and p38 inhibitors, suggesting that small molecule inhibition of p38 and MK2 may be a more effective method than genetic targeting for suppression of blistering. The expression pattern of Dsg3 in the epidermis in WT, MK2 KO, and p38 KO mice were similar, as determined by direct immunofluorescence staining of Dsg3 (data not shown). It is possible that the requirement for p38 or MK2 is different downstream of Dsg3 and Dsg1 in the suprabasal versus superficial epidermis ([@R26]), for example due to differential compensation by other proteins such as MK3, MK5, or other p38 isoforms, or that the superficial epidermis is more subject to frictional shear stress than the suprabasal epidermis.

Consistent with our studies on p38, we observe MK2-dependent and independent mechanisms of blister formation. In our models, Nikolsky skin fragility is p38- and MK2-independent, evidenced in mice with a genetic deletion of p38α in the epidermis ([@R18]), MK2 knockout mice, and wild type mice treated with MK2 inhibitors ([Figure 5](#F5){ref-type="fig"}). We believe this is the first step in disease pathology, reflecting steric hindrance of Dsg adhesion by binding of pathogenic anti-Dsg antibodies followed by mechanical shear stress. In contrast, signaling-dependent pathology is evaluated in our mouse models by spontaneous blistering, which occurs later than Nikolsky skin fragility and is inhibited by genetic deletion of MK2 or small molecule inhibition of p38 and MK2 ([Figure 6](#F6){ref-type="fig"}). These late events may reflect amplification of pathology by activation of p38, which causes endocytosis of multiple desmosomal molecules including Dsg3 and desmocollin 3, leading to desmosome disassembly ([@R17];[@R18]).

There are some discrepancies between our models and studies using PV IgG. Blister formation by PV serum IgG, but not a pathogenic mouse AK23 mAb, was blocked by p38 inhibition in human skin explants, which is primarily a test of Nikolsky fragility ([@R23]). PV serum IgG may have additional signaling-dependent pathogenic mechanisms related to Dsg3 clustering, causing more effective disassembly of desmosomes (whereas mAbs primarily deplete non-desmosomal Dsg3, with indirect effects on desmosome disassembly ([@R17])). Induced blisters after passive transfer of PV serum IgG to mice were also blocked by p38 inhibition ([@R5]). The latter study used lower doses for histologic versus gross blister evaluation, suggesting that the p38-dependence of induced blisters may be dose-dependent. Nevertheless, our models using human anti-Dsg IgG4 mAbs offer the advantage of being able to directly identify pathologic effects due to anti-Dsg antibodies in PV serum IgG and consistently reproduce key aspects of disease pathology caused by PV serum IgG, including activation of p38, Dsg endocytosis, and suprabasal blisters in human and mouse skin.

In summary, our results suggest that MK2 is the major pathologic downstream effector of p38 signaling in pemphigus. Future studies aim to establish a direct connection between MK2 activation and the cell pathologic effects of PV autoantibodies, including potential effects on other desmosomal proteins such as desmocollin, desmoplakin, and keratin. MK2 directly phosphorylates the actin-modulating protein HSP27 ([@R28]), which is activated in pemphigus ([@R3]). Additionally, MK2 phosphorylates keratins 18 and 20 in intestinal epithelial cells ([@R19]). Since collapse of the keratin intermediate filament network is a prominent cytologic finding in PV, it is possible that spontaneous blistering may be directly linked to regulation of the cytoskeletal network by MK2.

Therapeutically, inhibition of MK2 activity represents a more targeted strategy aimed to block the pathologic response of the skin to pemphigus autoantibodies, without generally suppressing patients' immunity. MK2 knockout mice are relatively resistant to endotoxic shock due to deficient production of tumor necrosis factor alpha, and this function is partially redundant with MAPKAP kinase 3 ([@R16];[@R22]). Therefore, MK2 inhibition may preserve systemic immunity while still inhibiting the pathologic effects of MK2 in skin keratinocytes. Inhibition of MK2, either topically or systemically, may represent a fast treatment option for PV during disease flare, allowing time for immunosuppressive agents to decrease pathogenic autoantibodies. Such interventions may be safer than topical or oral corticosteroids, which are currently used for rapid disease control.

Materials and Methods {#S9}
=====================

Antibodies and reagents {#S10}
-----------------------

Antibodies included rabbit anti-p38, anti-MK2, anti-phospho-p38 (Thr180/Tyr182), anti-phospho-MK2 (Thr222, Cell Signaling Technology, Danvers, MA), mouse anti-Dsg3 (5G11, Invitrogen, Grand Island, NY), mouse anti-desmoplakin (BioDesign International, Cincinnati, OH), mouse anti-keratin 14 (K14, Abcam Inc., Cambridge, MA), rabbit anti-histone H3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), HRP-conjugated donkey anti-mouse or -rabbit IgG (Jackson ImmunoResearch, West Grove, PA), Alexa 488-conjugated donkey anti-rabbit IgG, Alexa 488-conjugated goat anti-mouse and rabbit IgG, and Alexa 594-conjugated goat anti-mouse, rat, or rabbit IgG (Invitrogen).

PV IgG4 mAbs were produced as described, expressing the (D31)2/29 pathogenic and (D31)12b/6 nonpathogenic variable regions (also previously described as P1 and NP1 ([@R17])) with an IgG4 heavy chain ([@R20];[@R21]).

Other reagents included p38 inhibitor (SB202190), hydrogen peroxide, and puromycin (Sigma-Aldrich, St. Louis, MO); MK2 inhibitor III, MK2 shRNA and control shRNA lentiviral particles (Santa Cruz Biotechnology).

Cell culture and treatments {#S11}
---------------------------

Primary human epidermal keratinocytes (PHEK) were obtained from the Penn Skin Disease Research Center and cultured as described ([@R17];[@R18]). For p38 or MK2 inhibition assays, cells were treated with 0--2 μM SB202190 or 0--5 μg/ml MK2 inhibitor, followed by 200 μg/mL PV mAbs or 200 μM H~2~O~2~. HaCat cells were maintained in 50% DK-SFM:50% DMEM containing 10% fetal bovine serum and penicillin/streptomycin.

Immunofluorescence {#S12}
------------------

Immunofluorescence was performed as described for PHEK ([@R17]) and mouse skin ([@R18]).

Subcellular fractionation/immunoblotting {#S13}
----------------------------------------

After incubation with PV mAbs, PHEK were chilled on ice and washed with ice-cold PBS. Cells were harvested in ice-cold PBS by centrifugation at 2,500 × g for 1 minute at 4°C, then lysed in buffer containing 10 mM Hepes (pH 7.6), 0.4 mM CaCl2, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT, 0.5 mM PMSF, 10 μg/mL aprotinin and leupeptin on ice for 10 minutes. Lysates were passaged 20 times through a 26-G insulin syringe, followed by centrifugation at 7,200 × g for 1 minute at 4°C. The supernatant (cytoplasmic fraction) was removed, and the remaining nuclear pellet was washed and solubilized in Laemmli sample buffer. Triton X-100 cell fractionation and immunoblotting were performed as described ([@R18]).

RNA interference {#S14}
----------------

MK2 and control lentiviral shRNA were used to infect HaCat cells according to manufacturer's protocols. 72 hours after transduction, cells were selected with media containing 5 Jg/ml puromycin. Transduced cells were treated with 50 μg/ml PV mAbs or 100 μM H~2~O~2~ for 24 hours prior to analysis.

Neonatal mouse passive transfer {#S15}
-------------------------------

p38 fl/fl;+/+ (WT) or p38 fl/fl;K14cre/+ (KO) mice ([@R18]), or MK2 KO mice ([@R16]) and wild type littermate controls were used for passive transfer studies. Newborn mice (1--3 days, 1.2--2.5 g) were injected intradermally with 25μg purified PV monoclonal IgG4, +/− intradermal injection of p38 or MK2 inhibitor 2 hours prior, and sacrificed 16--18 hours after the last injection for evaluation. Skin sections were processed as described ([@R18]). Histology scores on serial sections were quantified as described ([@R27]).

Histology/immunohistochemistry {#S16}
------------------------------

Formalin-fixed, paraffin-embedded mouse skin sections were stained with hematoxylin and eosin according to standard procedures. Human pemphigus skin sections were obtained from the Penn Skin Disease Research Center Tissue Bank. Immunohistochemistry was performed to evaluate MK2 activation as described ([@R18]), incubating a rabbit anti-phospho-MK2 antibody (1:500) with sections overnight at 4°C, followed by peroxidase-conjugated donkey anti-rabbit IgG for one hour at room temperature.

Statistical Analysis {#S17}
--------------------

[Figures 5A,5D](#F5){ref-type="fig"},[6A,6D](#F6){ref-type="fig"}: Fisher's exact test. [Figures 5F](#F5){ref-type="fig"},[6C](#F6){ref-type="fig"}: Wilcoxon rank sum test. [Figures 5C](#F5){ref-type="fig"},[6F](#F6){ref-type="fig"}: Kruskal-Wallis test with Dunn's post-hoc multiple comparisons analysis to identify significant differences. p\<0.05 was considered significant.
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![MK2 is activated in lesional skin keratinocytes from pemphigus vulgaris (PV) and foliaceus (PF) patients\
Activated MK2, demonstrated by immunohistochemical staining of pemphigus skin biopsy samples with an antibody specific for phospho-MK2, was markedly increased in PV (PV1-4) and PF (PF1-2) lesional skin keratinocytes. No significant activation was observed in normal human skin or PV non-lesional keratinocytes (arrows indicate focal activation in perilesional keratinocytes). Normal rabbit serum was used as antibody negative control. Activated MK2 is primarily observed in the cytoplasm of keratinocytes (PV4 and PF1, inset). Scale bar=100μm.](nihms475957f1){#F1}

![Pathogenic but not nonpathogenic PV mAbs activate MK2 in primary human keratinocytes\
**A)** Pathogenic (P) mAb activates MK2 in a dose-dependent manner (treatment 2 hours), while nonpathogenic (NP) mAb does not, similar to positive controls for p38 activation by P mAb and oxidative stress (H~2~O~2~). **B)** Peak activation of MK2 by 50 μg/mL P mAb occurs at 2 hours. **C)** MK2 translocates from the nucleus to the cytosol after treatment of keratinocytes with P mAb. MK2 protein levels in the cytosolic and nuclear fractions (co-fractionation with beta-tubulin and histone, respectively) were detected by immunoblot. **D)** P mAb and H~2~O~2~, but not NP mAb, cause MK2 translocation from the nucleus to the cytosol at 4 hours, demonstrated by immunofluorescence. Scale bar=20μm.](nihms475957f2){#F2}

![MK2 inhibition blocks loss of cell surface Dsg3 by pathogenic (P) PV mAb\
**A)** Pretreatment of PHEK with an MK2-specific inhibitor (MK2I) for 2 hours, then PV mAb for 2 hours, blocks phosphorylation of HSP27 but not p38 in a dose-dependent pattern. **B)** MK2I rescues the loss of desmosomal Dsg3 caused by P mAb. PHEK were treated with DMSO, 2μM SB202190 (p38 inhibitor) or 2.5 μg/mL MK2I for 2 hours, followed by 50 μg/ml PV mAbs (P or NP) for 6 hours. Triton X-100-insoluble fractions were immunoblotted with antibodies as indicated. Data are representative of three independent experiments. **C)** P but not NP mAb (as in **B**) causes loss of cell surface Dsg3 (green), which is inhibited by SB202190 and MK2I. Scale bar=20μm.](nihms475957f3){#F3}

![Silencing of MK2 expression prevents PV mAb-induced loss of cell surface Dsg3\
**A)** HaCat cells that stably express MK2 shRNA (shRNA) show markedly reduced MK2 and p38 protein levels compared to cells expressing control (Ctl) shRNA. Levels of histone H3 are shown as a loading control. **B)** Immunofluorescence staining of HaCat cells expressing MK2 or control (Ctl) shRNA confirms knockdown of MK2 expression 72 hours after transduction. **C)** shRNA silencing of MK2 expression decreases loss of cell surface Dsg3 (shown in red) 16 hours after treatment with pathogenic PV mAb (P) and oxidative stress (H~2~O~2~). Scale bar=20μm.](nihms475957f4){#F4}

![Nikolsky (induced) blisters are not inhibited by genetic deletion or small molecule inhibition of MK2\
25 μg of pathogenic (P), but not nonpathogenic (NP), mAb caused Nikolsky blisters (arrows) 6 hours after mAb injection then mechanical shear stress in MK2-knockout (KO) and wild-type (WT) littermate control mice **(A)**, and wild-type mice pretreated with DMSO or MK2I **(D). (B, E)** Histologic analysis demonstrates suprabasal acantholysis in mice injected with P but not NP mAb. The extent of histologic blistering was significantly different between P and NP mAb, but similar in WT and MK2 KO mice injected with P mAb **(C)**, as well as wild-type mice injected with P mAb after pretreatment with DMSO or MK2I **(F)**. Scale bar=100 μm. \*\*p\<0.01; \*p\<0.05; NS, non-significant](nihms475957f5){#F5}

![Spontaneous blistering is inhibited by genetic deletion of MK2 and p38 or MK2 small molecule inhibition\
**A)** 16 hours after pathogenic (P) mAb injection, spontaneous blisters occur in wild-type (WT) (arrows) but not MK2-knockout (KO) mice. **B)** Histology shows suprabasal acantholysis in WT mice. 11/15 KO mice did not blister (left). 4/15 KO mice with gross blisters demonstrated superficial, not suprabasal, acantholysis (right). **C)** Suprabasal histologic blistering was significantly decreased in KO versus WT mice. **D)** SB202190 or MK2I prevents spontaneous blistering by P mAb (arrow). **E)** P but not NP mAbs cause suprabasal acantholysis, inhibited by SB202190 or MK2I, with focal blistering in some sections. **F)** Histologic blistering was significantly decreased by SB202190 and MK2I. Scale bar=100 μm. \*\*p\<0.01; \*p\<0.05; NS, non-significant.](nihms475957f6){#F6}
